Gold prices steady ahead of Fed decision; weekly weakness noted
SEATTLE - Atossa Therapeutics, Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company trading at $0.80 per share with a market cap of $103 million, announced today the issuance of a new patent by the United States Patent and Trademark Office (USPTO) for its breast cancer treatment formulations. According to InvestingPro data, the company has demonstrated strong recent momentum with an 8% return over the past week. The patent, U.S. Patent No. 12,281,056, covers enteric oral formulations of (Z)-endoxifen, a Selective Estrogen Receptor Modulator (SERM), and its therapeutic use.
The patent includes 58 claims related to the formulations’ purity and stability, as well as methods for their use in treating breast cancer. This addition strengthens Atossa’s intellectual property portfolio around its proprietary (Z)-endoxifen formulations, which are being developed for a range of breast cancer treatments, including prevention and metastatic breast cancer. The company maintains a strong financial position, with InvestingPro analysis showing a healthy current ratio of 15, indicating robust short-term liquidity.
Steven Quay, M.D., Ph.D., President and CEO of Atossa, expressed confidence in the potential of (Z)-endoxifen to improve the lives of millions of women facing breast cancer, while also creating value for shareholders. The company’s ongoing patent strategy supports its leadership in developing targeted therapies for hormone receptor-positive breast cancer.
(Z)-endoxifen is known for its potent estrogen receptor inhibition and may lead to estrogen receptor degradation. It has shown efficacy in patients resistant to other hormonal treatments and has been found to target PKCβ1, an oncogenic protein, at clinically attainable blood concentrations. Atossa’s oral formulation of (Z)-endoxifen is designed to bypass the stomach, preventing the conversion to inactive forms of the drug.
The company continues to advance its clinical research programs, aiming to improve patient outcomes and provide sustainable shareholder value. While analysts maintain a bullish outlook with price targets ranging from $4 to $7.25, InvestingPro analysis indicates the stock is currently fairly valued. Atossa Therapeutics’ commitment to innovation in breast cancer treatment is evident in its robust patent estate, which includes over 200 patent claims related to (Z)-endoxifen formulations and their clinical applications. For deeper insights into Atossa’s financial health and growth prospects, investors can access comprehensive analysis and additional ProTips through InvestingPro’s detailed research reports.
This news is based on a press release statement from Atossa Therapeutics, Inc.
In other recent news, Atossa Therapeutics has reported its Q4 2024 earnings, with an earnings per share (EPS) of -0.04, surpassing the forecasted -0.065. This better-than-expected performance highlights the company’s financial improvement, attributed to reduced operating expenses and disciplined spending. Atossa Genetics also announced a new patent for its (Z)-endoxifen formulation, aimed at treating hormone-dependent breast and reproductive tract disorders, strengthening its intellectual property portfolio. The company is advancing its lead program, (Z)-endoxifen, in metastatic breast cancer, with a focus on regulatory approval and market expansion. H.C. Wainwright has maintained a Buy rating for Atossa Genetics, emphasizing the strategic focus on (Z)-endoxifen’s clinical development. The upcoming Phase 3 SMART 2.0 trial will evaluate the efficacy of (Z)-endoxifen in reducing interval breast cancer, aiming to provide pivotal data for regulatory approval. These developments reflect Atossa’s ongoing efforts in breast cancer treatment and prevention.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.